📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Beta Drugs Q3 Results: PAT at ₹8.51 Cr; FY26 Revenue Guidance Cut to ₹400 Cr
Beta Drugs reported flat year-on-year revenue of ₹89.58 Crores for Q3 FY26, as a 33% surge in high-margin own branded sales was offset by a strategic exit from the low-margin CDMO Platin business. While gross margins improved significantly to 59% from 52%, EBITDA margins remained stable at 22% due to increased hiring in regulatory and manufacturing teams. The company has revised its FY26 revenue guidance downward to ₹400 Crores from ₹420 Crores but set an ambitious FY27 target of ₹530 Crores. Net profit was impacted by rising interest costs, which climbed to ₹4.43 Crores due to CCD interest obligations.
Key Highlights
Total Revenue stood flat at ₹89.58 Crores, while own branded sales grew strongly by 33% YoY.
Gross Margins saw a sharp increase to 59% in Q3FY26 compared to 52% in the previous year.
FY26 revenue outlook revised downward to ₹400 Crores due to the strategic de-focus on the Platin segment.
Interest expenses rose to ₹4.43 Crores from ₹1.87 Crores YoY, primarily on account of interest on CCDs.
Management projects FY27 revenue of ₹530 Crores with 24% EBITDA margins, driven by NDDS product launches.
💼 Action for Investors
Investors should focus on the company's successful transition toward higher-margin own brands and NDDS products despite the short-term revenue stagnation. Monitor the execution of the FY27 growth targets and the impact of geopolitical tensions on export recovery.
Beta Drugs Revises Valuation Report for Nivian Life Sciences Acquisition Using Consolidated Data
Beta Drugs Limited has announced a revision to the valuation report prepared for its proposed acquisition of Nivian Life Sciences Private Limited via a preferential issue. The registered valuer, Mr. Hitesh Jhamb, updated the report to use consolidated financial statements instead of the standalone figures used previously. This adjustment was made to provide a more comprehensive financial position under the Income and Cost approaches. The revised report, dated January 8, 2026, is now available for public inspection on the company's website.
Key Highlights
Revision of valuation report for the acquisition of Nivian Life Sciences Private Limited
Shift from standalone to consolidated financial statements for valuation methodology
Valuation updated for both Income Approach and Cost Approach metrics
Revised report dated January 8, 2026, replaces the previous version for the preferential issue
Disclosure made under Regulation 30 of SEBI LODR Regulations
💼 Action for Investors
Investors should review the revised valuation report on the company website to see if the shift to consolidated financials impacts the final issue price or dilution. Monitor for further updates on the approval of the preferential issue.
Beta Drugs Shareholders Approve Preferential Issue of 2.84 Lakh Shares at ₹1,712.49
Beta Drugs Limited held an Extraordinary General Meeting on February 4, 2026, where shareholders unanimously approved all proposed resolutions. A key outcome is the approval of a preferential issue of 2,83,668 equity shares at a price of ₹1,712.49 per share, which includes a significant premium of ₹1,702.49. Additionally, the company received approval for its Employee Stock Option Plan (ESOP) 2026 and an increase in authorized share capital. These moves indicate a focus on capital infusion and talent retention through equity-based incentives.
Key Highlights
Unanimous approval (100% in favor) for the issuance of 2,83,668 equity shares on a preferential basis.
Preferential issue price set at ₹1,712.49 per share, featuring a premium of ₹1,702.49 over the ₹10 face value.
Approval of the 'Beta Drugs Limited Employee Stock Option Plan 2026' for both company and group employees.
Authorized share capital increased and Memorandum of Association altered to facilitate the new share issuance.
Total of 5,969,737 valid votes were cast across all resolutions with zero votes against.
💼 Action for Investors
Investors should view the successful fundraising at a high premium as a positive sign of valuation confidence. Monitor the specific use of proceeds from the preferential issue and the long-term impact of the ESOP on employee retention and equity dilution.
Beta Drugs Approves ₹48.58 Cr Fundraise via Preferential Issue and New ESOP 2026 Plan
Beta Drugs Limited held an Extraordinary General Meeting on February 04, 2026, where shareholders approved a significant fundraise through a preferential issue. The company will issue 2,83,668 equity shares at a price of ₹1712.49 per share, including a premium of ₹1702.49, totaling approximately ₹48.58 crore. Additionally, the 'Beta Drugs Limited Employee Stock Option Plan 2026' was approved to incentivize employees across the group and subsidiaries. These moves are supported by an increase in the company's Authorized Share Capital to facilitate the new issuances.
Key Highlights
Approved preferential issue of 2,83,668 equity shares at a price of ₹1712.49 per share
Total capital infusion through the preferential offer amounts to approximately ₹48.58 crore
Launch of 'Employee Stock Option Plan 2026' for employees of the company and its group entities
Increase in Authorized Share Capital and alteration of the Memorandum of Association approved
Preferential issue price includes a significant premium of ₹1702.49 over the ₹10 face value
💼 Action for Investors
Investors should view the fundraise at a high premium as a sign of strong valuation support and confidence from specific investors. Monitor the company's upcoming disclosures regarding the specific utilization of these funds for expansion or debt reduction.
Beta Drugs to Acquire Nivian Lifesciences Stake via INR 48.57 Cr Share Swap; Proposes ESOP 2026
Beta Drugs Limited has scheduled an EGM for February 4, 2026, to approve a strategic acquisition of Nivian Lifesciences Private Limited via a share swap arrangement. The company will issue 2,83,668 equity shares at a price of INR 1,712.49 per share to the sellers of the target company, representing a total value of approximately INR 48.57 crore. Additionally, the board has proposed an ESOP 2026 scheme for 2,00,000 shares (1.98% of paid-up capital) to incentivize employees. To facilitate these issuances, the authorized share capital is being raised from INR 11 crore to INR 11.40 crore.
Key Highlights
Issuance of 2,83,668 shares at INR 1,712.49 each for a non-cash consideration (share swap) to acquire Nivian Lifesciences
Proposed ESOP 2026 plan involving 2,00,000 shares, representing 1.98% of the paid-up equity as of March 2025
Authorized share capital to be increased from INR 11,00,00,000 to INR 11,40,00,000
Acquisition involves key allottees including Anjali Ajit Deval and Kayadam Ramanathan Bharat
The issue price includes a substantial premium of INR 1,702.49 per share over the face value of INR 10
💼 Action for Investors
Investors should monitor the integration and growth potential of Nivian Lifesciences to justify the share dilution. The high issue price indicates strong internal valuation and confidence in the company's growth trajectory.
Beta Drugs to Acquire 66.09% Stake in Nivian Lifesciences for INR 69.4 Crores
Beta Drugs Limited has entered into a definitive agreement to acquire a 66.09% stake in Nivian Lifesciences, a fast-growing player in the In-Vitro Fertilisation (IVF) segment. The acquisition is valued at INR 69.4 Crores, implying a total valuation of INR 105 Crores for Nivian. Nivian reported net sales of INR 30.30 Crores for the 9 months ended December 2025 and is projected to reach approximately INR 43 Crores by the end of FY26. This strategic move allows Beta Drugs to diversify its portfolio into the high-growth women's health and fertility market, which is currently expanding at a 20% CAGR.
Key Highlights
Acquisition of 66.09% stake in Nivian Lifesciences for INR 69.4 Crores, valuing the company at INR 105 Crores.
Nivian reported 9M Dec'25 net sales of INR 30.30 Crores with a FY26 revenue target of ~INR 43 Crores.
Entry into the IVF therapy market, which has a total addressable size of INR 1,500-1,700 Crores in India.
Strategic synergy combining Beta's manufacturing capabilities with Nivian's marketing expertise in niche formulations.
Founder Nilesh Auti will continue to lead Nivian's operations and remain a minority shareholder.
💼 Action for Investors
Investors should look favorably on this acquisition as it provides Beta Drugs entry into a high-margin, high-growth niche segment. Monitor the post-acquisition integration and the impact on consolidated earnings in the coming fiscal year.
Beta Drugs to Acquire 66.09% Stake in Nivian Lifesciences for INR 69.4 Crores
Beta Drugs Limited has signed a definitive agreement to acquire a 66.09% majority stake in Nivian Lifesciences, valuing the target at INR 105 Crores. Nivian is a high-growth player in the In-Vitro Fertilisation (IVF) segment, which has experienced a 20% CAGR over the last five years. Nivian reported net sales of INR 30.30 Crores for the nine months ending December 2026 and expects to close FY27 at approximately INR 43 Crores. This acquisition enables Beta Drugs to diversify its portfolio into women's health and fertility, complementing its existing strengths in oncology and cosmetology.
Key Highlights
Acquisition of 66.09% stake for INR 69.4 Crores, implying a total valuation of INR 105 Crores for Nivian.
Nivian projects FY27 revenue of ~INR 43 Crores, following a strong 9M performance of INR 30.30 Crores.
Entry into the IVF therapy market, which has an estimated total market size of INR 1,500-1,700 Crores.
Strategic synergy combines Beta's manufacturing cost leadership with Nivian's specialized IVF marketing and sales expertise.
Founder Nilesh Auti will continue to lead Nivian's operations, ensuring management continuity and expertise retention.
💼 Action for Investors
Investors should look favorably on this acquisition as it provides Beta Drugs with a high-growth vertical outside of oncology. Monitor the post-acquisition integration and the impact on consolidated EBITDA margins in the coming fiscal year.
Beta Drugs to Acquire 66.09% Stake in Nivian Life Sciences for ₹69.40 Crores
Beta Drugs has approved the acquisition of a 66.09% majority stake in Nivian Life Sciences, a specialist in the high-growth In-Vitro Fertilisation (IVF) therapy segment. The total consideration of ₹69.40 crores will be settled through a mix of ₹20.82 crores in cash and ₹48.58 crores via a share swap, issuing 2,83,668 shares at ₹1,712.49 per share. Nivian reported a turnover of ₹29.12 crores and an EBITDA of ₹4.22 crores for FY25. The board also approved a new ESOP scheme for 2,00,000 shares and an increase in authorized share capital.
Key Highlights
Acquisition of 66.09% stake in Nivian Life Sciences for a total value of ₹69.40 Crores
Consideration includes ₹20.82 Cr cash and issuance of 2,83,668 equity shares at ₹1,712.49 each
Target entity Nivian Life Sciences achieved FY25 turnover of ₹29.12 Cr and EBITDA of ₹4.22 Cr
Implementation of 'ESOP 2026' plan covering up to 2,00,000 equity shares for employees
Authorized share capital increased from ₹11.00 Cr to ₹11.40 Cr to facilitate the share swap
💼 Action for Investors
Investors should monitor the integration of Nivian's IVF portfolio, which offers high-growth synergies with Beta's existing oncology distribution network. The acquisition valuation at approximately 16.4x EBITDA appears strategic for entry into a niche pharmaceutical segment.
Beta Drugs to Consider Acquisition and Preferential Share Issue on January 9
Beta Drugs Limited has scheduled a board meeting for January 9, 2026, to deliberate on a strategic acquisition of a target company. The company intends to issue equity shares on a preferential basis to the target's shareholders as consideration for the deal, effectively an equity swap. Additionally, the board will consider the implementation of an Employee Stock Option Plan (ESOP). The trading window remains closed as these developments are deemed price-sensitive alongside the upcoming financial results.
Key Highlights
Board meeting scheduled for January 9, 2026, to approve a target company acquisition.
Proposed issuance of equity shares on a preferential basis as non-cash consideration for the acquisition.
Introduction of an Employee Stock Option Plan (ESOP) to be considered by the board.
Trading window closure extended until 48 hours after the declaration of financial results.
The acquisition and share issuance are classified as price-sensitive information under SEBI regulations.
💼 Action for Investors
Investors should watch for the January 9 board outcome to understand the valuation of the target company and the extent of equity dilution. The move indicates an aggressive inorganic growth strategy which could be a long-term positive for the stock.
Beta Drugs Board to Consider Acquisition and Preferential Issue on January 9, 2026
Beta Drugs Limited has scheduled a board meeting on January 9, 2026, to deliberate on the acquisition of a target company. The transaction is structured to involve the purchase of shares from the target's shareholders in exchange for new equity shares of Beta Drugs issued on a preferential basis. Furthermore, the board will evaluate the introduction of an Employee Stock Option Plan (ESOP). This strategic move suggests a focus on inorganic expansion and long-term employee alignment through equity-based incentives.
Key Highlights
Board meeting set for January 9, 2026, to approve a strategic acquisition of a target company.
Proposed issuance of equity shares on a preferential basis as non-cash consideration for the acquisition.
The board will also consider and approve the implementation of an Employee Stock Option Plan (ESOP).
The acquisition involves purchasing equity directly from the existing shareholders of the target entity.
💼 Action for Investors
Investors should monitor the January 9 board outcome for details regarding the target company's valuation and the potential equity dilution from the preferential issue. The move signals aggressive growth ambitions, which could be a positive long-term catalyst for the stock.